Background: The Tei index simultaneously evaluates the ventricular systolic and diastolic functions. It has a good correlation with hemodynamic data and has enabled the detection of initial ventricular function alterations of different etiologies.
Objective: To study initial biventricular function alterations in chagasic patients with no apparent heart disease, using the Tei index.
Methods: Forty eight individuals were evaluated. Group 1 was comprised of 25 patients diagnosed with Chagas' disease with no apparent heart disease and normal echocardiogram; group 2 was comprised of 23 healthy individuals with negative serological tests for Chagas' disease.
Results: The Tei index was significantly higher in the group of chagasic patients with no apparent heart disease when compared to that of the control group: left ventricular Tei index (0.48 +/-0.11 vs. 0.36 +/- 0.06, p < 0.001) , right ventricular Tei index (0.34 +/- 0.10 vs. 0.26 +/- 0.07, p = 0.001). The left and right ventricular Tei indexes were considered abnormal in 48% and 28% of the chagasic patients, respectively.
Conclusion: Chagasic patients with no apparent heart disease present early alterations of the right and left ventricles.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/s0066-782x2007001800006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic Evaluation of Chagasic and Non-Chagasic Patients Undergoing Pacemaker Implantation and Cardiac Resynchronization in a Tertiary Center.
Arq Bras Cardiol
October 2024
Programa de Pós-graduação em Ciências Aplicadas à Saúde do Adulto - Departamento de Clínica Médica - Faculdade de Medicina e Serviço de Cardiologia e Cirurgia Cardiovascular do Hospital das Clínicas da Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG - Brasil.
Background: Chagas cardiomyopathy (ChCC) is one of the causes of the implantation of pacemakers (PM) in many patients and has been associated with an adverse prognosis.
Objectives: To compare the prognosis of the chagasic and non-chagasic populations undergoing PM and cardiac resynchronizer implantation.
Methods: Observational, retrospective study, which analyzed a cohort of patients who underwent implantation of these devices, in a tertiary center, from October 2007 to December 2017, comparing the chagasic group with non-chagasic patients.
Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy: The CHAGASICS Randomized Clinical Trial.
JAMA Cardiol
December 2024
Department of Cardiology, Instituto do Coração, Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil.
Importance: Over 10 000 people with Chagas disease experience sudden cardiac death (SCD) annually, mostly caused by ventricular fibrillation. Amiodarone hydrochloride and the implantable cardioverter-defibrillator (ICD) have been empirically used to prevent SCD in patients with chronic Chagas cardiomyopathy.
Objective: To test the hypothesis that ICD is more effective than amiodarone therapy for primary prevention of all-cause mortality in patients with chronic Chagas cardiomyopathy and moderate to high mortality risk, assessed by the Rassi score.
Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy: Rationale and Design of the PARACHUTE-HF Trial.
JACC Heart Fail
August 2024
Brazilian Clinical Research Institute (BCRI), São Paulo, Brazil; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address:
Chronic Chagas cardiomyopathy (CCC) has unique pathogenic and clinical features with worse prognosis than other causes of heart failure (HF), despite the fact that patients with CCC are often younger and have fewer comorbidities. Patients with CCC were not adequately represented in any of the landmark HF studies that support current treatment guidelines. PARACHUTE-HF (Prevention And Reduction of Adverse outcomes in Chagasic Heart failUre Trial Evaluation) is an active-controlled, randomized, phase IV trial designed to evaluate the effect of sacubitril/valsartan 200 mg twice daily vs enalapril 10 mg twice daily added to standard of care treatment for HF.
View Article and Find Full Text PDFCrosstalk between cytokines, inflammation and pulmonary arterial hypertension in heart transplant patients.
Cytokine
October 2024
Department of Cardiovascular Surgery, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Background: Heart transplant (HT) is a therapeutic option for patients with advanced heart failure (HF) refractory to optimized treatment. Patients with advanced HF often develop pulmonary arterial hypertension (PAH). PAH is defined as a condition in which the mean pulmonary artery pressure is greater than 20 mmHg.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!